Figure S7 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody

Authors :: Shahram Salek-Ardakani
John C. Lin
Arvind Rajpal
Eugenia Kraynov
Jeffrey Chou
Jerry D. Clark
Allison Xu
Christopher P. Dillon
Natalija Budimir
Brent Kern
Bart Jessen
Cris Kamperschroer
Sherman M. Chin
Christopher R. Kimberlin
Joyce Chou
HoangKim Nguyen
Yasmina Abdiche
Sawsan Youssef
Amir A. Al-Khami
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplementary Figure 7 shows the binding of sasanlimab to PD-1 by ELISA

Full Text Access

Tools